PL2275103T3 - Inhibitory mTOR w leczeniu nowotworów neuroendokrynnych - Google Patents

Inhibitory mTOR w leczeniu nowotworów neuroendokrynnych

Info

Publication number
PL2275103T3
PL2275103T3 PL10175197T PL10175197T PL2275103T3 PL 2275103 T3 PL2275103 T3 PL 2275103T3 PL 10175197 T PL10175197 T PL 10175197T PL 10175197 T PL10175197 T PL 10175197T PL 2275103 T3 PL2275103 T3 PL 2275103T3
Authority
PL
Poland
Prior art keywords
treatment
mtor inhibitors
endocrine tumors
endocrine
tumors
Prior art date
Application number
PL10175197T
Other languages
English (en)
Inventor
Peter Wayne Marks
David Lebwohl
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37671355&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2275103(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0523658A external-priority patent/GB0523658D0/en
Priority claimed from GB0601082A external-priority patent/GB0601082D0/en
Priority claimed from GB0602747A external-priority patent/GB0602747D0/en
Priority claimed from GB0607942A external-priority patent/GB0607942D0/en
Priority claimed from GB0609272A external-priority patent/GB0609272D0/en
Priority claimed from GB0609912A external-priority patent/GB0609912D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PL2275103T3 publication Critical patent/PL2275103T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PL10175197T 2005-11-21 2006-11-20 Inhibitory mTOR w leczeniu nowotworów neuroendokrynnych PL2275103T3 (pl)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
GB0523658A GB0523658D0 (en) 2005-11-21 2005-11-21 Organic compounds
GB0601082A GB0601082D0 (en) 2006-01-19 2006-01-19 Organic Compounds
GB0602747A GB0602747D0 (en) 2006-02-10 2006-02-10 Organic compounds
GB0607942A GB0607942D0 (en) 2006-04-21 2006-04-21 Organic compounds
GB0609272A GB0609272D0 (en) 2006-05-10 2006-05-10 Organic compounds
GB0609912A GB0609912D0 (en) 2006-05-18 2006-05-18 Organic compounds
EP06120660 2006-09-14
EP06819607A EP1954269A2 (en) 2005-11-21 2006-11-20 Neuroendocrine tumor treatment using mtor inhibitors
EP08162295A EP2022498A3 (en) 2005-11-21 2006-11-20 Neuroendocrine tumour treatment
EP10175197.2A EP2275103B1 (en) 2005-11-21 2006-11-20 mTOR inhibitors in the treatment of endocrine tumors

Publications (1)

Publication Number Publication Date
PL2275103T3 true PL2275103T3 (pl) 2014-09-30

Family

ID=37671355

Family Applications (1)

Application Number Title Priority Date Filing Date
PL10175197T PL2275103T3 (pl) 2005-11-21 2006-11-20 Inhibitory mTOR w leczeniu nowotworów neuroendokrynnych

Country Status (22)

Country Link
US (3) US9006224B2 (pl)
EP (3) EP2022498A3 (pl)
JP (3) JP2009516671A (pl)
KR (2) KR20080071600A (pl)
CN (1) CN103446138A (pl)
AU (2) AU2006314444C1 (pl)
BR (1) BRPI0618808A2 (pl)
CA (2) CA2629245C (pl)
CY (1) CY1115299T1 (pl)
DK (1) DK2275103T3 (pl)
ES (1) ES2481671T3 (pl)
HK (1) HK1150746A1 (pl)
HR (1) HRP20140708T1 (pl)
IL (3) IL191475A (pl)
MA (1) MA29966B1 (pl)
NO (4) NO20220050A1 (pl)
NZ (1) NZ568182A (pl)
PL (1) PL2275103T3 (pl)
PT (1) PT2275103E (pl)
RU (1) RU2487711C2 (pl)
SI (1) SI2275103T1 (pl)
WO (1) WO2007057457A2 (pl)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1363627A2 (en) 2001-02-19 2003-11-26 Novartis AG Treatment of solid tumours with rapamycin derivatives
KR20140020367A (ko) * 2006-04-05 2014-02-18 노파르티스 아게 암을 치료하기 위한 ｂｃｒ-ａｂｌ/ｃ-ｋｉｔ/ｐｄｇｆ-ｒ ｔｋ 억제제를 포함하는 조합물
US20090098137A1 (en) * 2006-04-05 2009-04-16 Novartis Ag Combinations of therapeutic agents for treating cancer
AU2013205002B2 (en) * 2008-03-21 2016-09-15 The University Of Chicago Treatment with opioid antagonists and mTOR inhibitors
JP5647098B2 (ja) * 2008-03-21 2014-12-24 ザ ユニヴァーシティー オヴ シカゴ オピオイド拮抗薬とｍＴＯＲ阻害薬を用いた治療
NZ591810A (en) 2008-09-17 2012-12-21 Chiasma Inc Pharmaceutical compositions and related methods of delivery the composition comprises a medium chain fatty acid
US9057054B2 (en) 2009-06-25 2015-06-16 The Regents Of The University Of Michigan Antigen-specific long-term memory T-cells
SI3050882T1 (en) 2010-03-10 2018-06-29 Incyte Holdings Corporation Piperidin-4-yl azetidine derivatives, as inhibitors of JAK1
UA115319C2 (uk) * 2011-10-19 2017-10-25 Сігнал Фармасьютікалз, Елелсі Лікування злоякісної пухлини інгібітором тоr-кінази
JP2016516671A (ja) * 2013-02-28 2016-06-09 シグナル ファーマシューティカルズ，エルエルシー Ｔｏｒキナーゼ阻害剤を用いたがんの治療
US20160015691A1 (en) * 2013-03-15 2016-01-21 The Board Of Regents Of The University Of Texas System Use of mtor inhibitors for prevention of neuroendocrine tumor development and growth
CN105407892B (zh) 2013-05-29 2019-05-07 西格诺药品有限公司 一种化合物的药物组合物、其固体形式及它们的使用方法
CA2933908C (en) 2013-12-31 2024-01-30 Rapamycin Holdings, Llc Oral rapamycin nanoparticle preparations and use
MA41462A (fr) 2015-02-03 2021-05-12 Chiasma Inc Méthode de traitement de maladies
US11045436B2 (en) * 2015-06-30 2021-06-29 Shanghai Jiao Tong University Applications for sulindac in preparing anti-lung cancer products
US20210187079A1 (en) * 2016-01-21 2021-06-24 Chiasma, Inc. Oral octreotide for the treatment of disease
WO2018204477A1 (en) * 2017-05-02 2018-11-08 Cornell University Methods and reagents for tumor targeting with greater efficacy and less toxicity
JP7282045B2 (ja) 2017-06-22 2023-05-26 セルジーン コーポレイション Ｂ型肝炎ウイルス感染を特徴とする肝細胞癌の治療
WO2019157363A2 (en) * 2018-02-09 2019-08-15 Mount Tam Therapeutics, Inc. Rapamycin analog for prevention and/or treatment of cancer
AU2019262979B2 (en) 2018-05-01 2023-07-06 Revolution Medicines, Inc. C26-linked rapamycin analogs as mTOR inhibitors
WO2020191002A1 (en) * 2019-03-18 2020-09-24 The Regents Of The University Of California Compositions and methods for treating cushing's disease
US11141457B1 (en) 2020-12-28 2021-10-12 Amryt Endo, Inc. Oral octreotide therapy and contraceptive methods
CA3220332A1 (en) * 2021-06-07 2022-12-15 Nanopharmaceuticals Llc Composition and method for dual targeting in treatment of neuroendocrine tumors
US11723888B2 (en) 2021-12-09 2023-08-15 Nanopharmaceuticals Llc Polymer conjugated thyrointegrin antagonists

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0100172B1 (en) 1982-07-23 1987-08-12 Imperial Chemical Industries Plc Amide derivatives
GB8327256D0 (en) 1983-10-12 1983-11-16 Ici Plc Steroid derivatives
IL86632A0 (en) 1987-06-15 1988-11-30 Ciba Geigy Ag Derivatives substituted at methyl-amino nitrogen
US5538739A (en) * 1989-07-07 1996-07-23 Sandoz Ltd. Sustained release formulations of water soluble peptides
US5010099A (en) 1989-08-11 1991-04-23 Harbor Branch Oceanographic Institution, Inc. Discodermolide compounds, compositions containing same and method of preparation and use
GB9013448D0 (en) 1990-06-15 1990-08-08 Sandoz Ltd Pharmaceutical resorption-improved somatostatin compositions,their preparation and use
PT98990A (pt) 1990-09-19 1992-08-31 American Home Prod Processo para a preparacao de esteres de acidos carboxilicos de rapamicina
NZ243082A (en) 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
GB9300059D0 (en) 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
TW225528B (pl) 1992-04-03 1994-06-21 Ciba Geigy Ag
ZA935112B (en) 1992-07-17 1994-02-08 Smithkline Beecham Corp Rapamycin derivatives
US5234140A (en) 1992-07-28 1993-08-10 S. C. Johnson & Son, Inc. Re-useable aerosol container
DK1167384T3 (da) 1992-10-28 2007-04-10 Genentech Inc Vaskular endotheliel cellevækstfaktor antagonister
GB9314893D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
IL129547A (en) 1994-10-26 2001-01-11 Novartis Ag Pharmaceutical compositions comprising a macrolide and an acid
PT817775E (pt) 1995-03-30 2002-01-30 Pfizer Derivados de quinazolina
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
HUP9900330A3 (en) 1995-07-06 2001-08-28 Novartis Ag Pyrrolopyrimidines and processes for the preparation thereof
IT1277391B1 (it) 1995-07-28 1997-11-10 Romano Deghenghi Peptidi ciclici analoghi della somatostatina ad attivita' inibitrice dell'ormone della crescita
US5760041A (en) 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
JP3370340B2 (ja) 1996-04-12 2003-01-27 ワーナー―ランバート・コンパニー チロシンキナーゼの不可逆的阻害剤
CA2249439C (en) * 1996-06-11 2009-09-08 Novartis Ag Combination of a somatostatin analogue and a rapamycin
BR9709959A (pt) 1996-06-24 2000-05-09 Pfizer Derivados tricìclicos de fenilamino substituìdo para o tratamento de doenças hiperproliferativas
US5932613A (en) 1996-07-03 1999-08-03 Millennium Pharmaceuticals, Inc. Anticancer agents
WO1998002441A2 (en) 1996-07-12 1998-01-22 Ariad Pharmaceuticals, Inc. Non immunosuppressive antifungal rapalogs
AU716610B2 (en) 1996-08-30 2000-03-02 Novartis Ag Method for producing epothilones, and intermediate products obtained during the production process
DE19638745C2 (de) 1996-09-11 2001-05-10 Schering Ag Monoklonale Antikörper gegen die extrazelluläre Domäne des menschlichen VEGF - Rezeptorproteins (KDR)
WO1998010767A2 (en) 1996-09-13 1998-03-19 Sugen, Inc. Use of quinazoline derivatives for the manufacture of a medicament in the treatment of hyperproliferative skin disorders
EP0837063A1 (en) 1996-10-17 1998-04-22 Pfizer Inc. 4-Aminoquinazoline derivatives
BR9713363B1 (pt) 1996-11-18 2011-02-08 processo para preparação de epotilona d.
US6441186B1 (en) 1996-12-13 2002-08-27 The Scripps Research Institute Epothilone analogs
CO4950519A1 (es) 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
CO4940418A1 (es) 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
GB9721069D0 (en) 1997-10-03 1997-12-03 Pharmacia & Upjohn Spa Polymeric derivatives of camptothecin
US6194181B1 (en) 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
NZ506742A (en) 1998-02-25 2003-09-26 Sloan Kettering Inst Cancer Synthesis of desoxyepothilones and hydroxy acid derivative intermediates
ES2342240T3 (es) 1998-08-11 2010-07-02 Novartis Ag Derivados de isoquinolina con actividad que inhibe la angiogenia.
GB9824579D0 (en) 1998-11-10 1999-01-06 Novartis Ag Organic compounds
UA71587C2 (uk) 1998-11-10 2004-12-15 Шерінг Акцієнгезелльшафт Аміди антранілової кислоти та їхнє застосування як лікарських засобів
WO2000031247A2 (en) 1998-11-20 2000-06-02 Kosan Biosciences, Inc. Recombinant methods and materials for producing epothilone and epothilone derivatives
EP2016953A3 (en) 1998-12-22 2009-04-15 Genentech, Inc. Vascular endothelial cell growth factor antagonists and uses thereof
AU766081B2 (en) 1999-03-30 2003-10-09 Novartis Ag Phthalazine derivatives for treating inflammatory diseases
EP1212331B1 (en) 1999-08-24 2004-04-21 Ariad Gene Therapeutics, Inc. 28-epirapalogs
RU2264405C2 (ru) 1999-12-06 2005-11-20 Новартис Аг 40-o-(2-гидрокси)этилрапамицин в кристаллической несольватированной форме, фармацевтическая композиция, содержащая такой макролид в качестве действующего вещества, и способ его получения
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
IL155618A0 (en) 2000-11-07 2003-11-23 Novartis Ag Indolylmaleimide derivatives as protein kinase c inhibitors
TWI286074B (en) * 2000-11-15 2007-09-01 Wyeth Corp Pharmaceutical composition containing CCI-779 as an antineoplastic agent
EP1363627A2 (en) 2001-02-19 2003-11-26 Novartis AG Treatment of solid tumours with rapamycin derivatives
TWI233359B (en) 2001-04-06 2005-06-01 Wyeth Corp Pharmaceutical composition for treating neoplasm
TWI296196B (en) 2001-04-06 2008-05-01 Wyeth Corp Antineoplastic combinations
HUP0304093A3 (en) * 2001-04-06 2008-08-28 Wyeth Corp Antineoplastic combinations containing and mtor inhibitor and an antimetabolic antineoplastic agent and pharmaceutical compositions containing them
UA78706C2 (en) 2001-06-01 2007-04-25 Wyeth Corp Combination of rapamycin derivative and antitumor alkylating agent and method for treating soft tissue sarcoma and colonic cancer
NZ529877A (en) * 2001-06-01 2006-08-31 Wyeth Corp Antineoplastic combinations
UA77200C2 (en) * 2001-08-07 2006-11-15 Wyeth Corp Antineoplastic combination of cci-779 and bkb-569
GB0119249D0 (en) 2001-08-07 2001-10-03 Novartis Ag Organic compounds
PL216224B1 (pl) 2002-02-01 2014-03-31 Ariad Pharmaceuticals Pochodne rapamycyny zawierające fosfor, kompozycja je zawierająca oraz ich zastosowanie
PE20040079A1 (es) 2002-04-03 2004-04-19 Novartis Ag Derivados de indolilmaleimida
US20060094674A1 (en) * 2002-07-05 2006-05-04 Neel Benjamin G Combination of mtor inhibitor and a tyrosine kinase inhibitor for the treatment of neoplasms
JP2006514021A (ja) 2002-12-09 2006-04-27 ザ・ボード・オブ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・テキサス・システム Ｊａｎｕｓチロシンキナーゼ３（Ｊａｋ３）を選択的に阻害するための方法
UA83484C2 (uk) 2003-03-05 2008-07-25 Уайт Спосіб лікування раку грудей комбінацією похідного рапаміцину і інгібітора ароматази - летрозолу, фармацевтична композиція
US7160867B2 (en) 2003-05-16 2007-01-09 Isotechnika, Inc. Rapamycin carbohydrate derivatives
EP1709449A1 (en) 2003-12-22 2006-10-11 Novartis AG Biomarkers for sensitivity of proliferative diseases to mtor inhibitors
DK1704145T3 (da) 2004-01-12 2012-09-24 Ym Biosciences Australia Pty Selektive kinaseinhibitorer
JP5005355B2 (ja) 2004-02-23 2012-08-22 ノバルティス アーゲー 細胞毒性因子と組み合わせたｍＴＯＲ阻害剤での処置のためのバイオマーカーとしてのｐ５３野生型
CA2556025A1 (en) * 2004-02-23 2005-09-09 Sugen, Inc. Method of treating abnormal cell growth using c-met and m-tor inhibitors
CA2589521C (en) * 2004-12-15 2014-04-01 Novartis Ag Combinations of 7-t-butoxyiminomethylcamptothecin with one or more chemotherapeutic agents for treating cancers
WO2006071966A2 (en) 2004-12-29 2006-07-06 The Brigham And Women's Hospital, Inc. Rapamycin compounds in the treatment of neurofibromatosis type 1

Also Published As

Publication number Publication date
US20150148294A1 (en) 2015-05-28
CA2933875A1 (en) 2007-05-24
EP2275103A2 (en) 2011-01-19
NO20220050A1 (no) 2008-08-12
CN103446138A (zh) 2013-12-18
CY1115299T1 (el) 2017-01-04
ES2481671T3 (es) 2014-07-31
DK2275103T3 (da) 2014-07-07
US9006224B2 (en) 2015-04-14
BRPI0618808A2 (pt) 2011-09-13
EP2022498A3 (en) 2012-08-15
RU2487711C2 (ru) 2013-07-20
KR20080071600A (ko) 2008-08-04
CA2629245C (en) 2016-07-12
CA2629245A1 (en) 2007-05-24
JP5963836B2 (ja) 2016-08-03
WO2007057457A2 (en) 2007-05-24
HK1150746A1 (en) 2012-01-13
NO344288B1 (no) 2019-10-28
JP2009516671A (ja) 2009-04-23
NO20082683L (no) 2008-08-12
SI2275103T1 (sl) 2014-07-31
NO20161045A1 (no) 2008-08-12
AU2006314444C1 (en) 2018-01-04
KR20140012218A (ko) 2014-01-29
NO341023B1 (no) 2017-08-07
EP2275103A3 (en) 2011-10-12
PT2275103E (pt) 2014-07-24
EP2275103B1 (en) 2014-04-23
HRP20140708T1 (hr) 2014-09-26
EP2022498A2 (en) 2009-02-11
IL250697A0 (en) 2017-04-30
AU2006314444B2 (en) 2010-08-26
EP1954269A2 (en) 2008-08-13
JP2013144706A (ja) 2013-07-25
NZ568182A (en) 2010-08-27
US20170128425A1 (en) 2017-05-11
US20080255029A1 (en) 2008-10-16
AU2006314444A1 (en) 2007-05-24
JP5833048B2 (ja) 2015-12-16
RU2008124827A (ru) 2009-12-27
AU2010202866A1 (en) 2010-07-29
NO20170956A1 (no) 2008-08-12
WO2007057457A3 (en) 2008-01-10
CA2933875C (en) 2018-06-26
NO346575B1 (no) 2022-10-17
MA29966B1 (fr) 2008-11-03
JP2015061868A (ja) 2015-04-02
IL253698A0 (en) 2017-09-28
IL191475A (en) 2017-08-31

Similar Documents

Publication Publication Date Title
PL2275103T3 (pl) Inhibitory mTOR w leczeniu nowotworów neuroendokrynnych
IL188430A0 (en) Treatment of tumors
PL2100618T3 (pl) Przeciwciało anty-PDGFR alfa do zastosowania w leczeniu przerzutowego raka kości
IL186447A0 (en) Methods for the treatment of substance abuse and dependence
HUE037109T2 (hu) Endoxifén rák kezelésében történõ alkalmazásra
GB0506759D0 (en) Combination treatment methods
IL176919A0 (en) Methods and compositions for treating cancer
EP1845970A4 (en) INHIBITORS OF TUMOR NECROSIS FACTOR
HK1215683A1 (zh) 抗葉酸藥在癌症治療中的聯合應用
PT1611890E (pt) Métodos para avaliação e tratamento do cancro
IL185258A (en) Oligodeoxyribonucleotides for use in the treatment of angiogenesis-dependent tumors in human
EP1830847A4 (en) CANCER TREATMENT
HK1117780A1 (en) Compounds and methods for the treatment of cancer
EP1855662A4 (en) METHODS AND COMPOSITIONS FOR TREATING CANCER
IL202307A0 (en) Multikinase inhibitors for use in the treatment of cancer
AU2006251167A8 (en) Tetrahydropyridothiophenes for use in the treatment of cancer
AU2006251169A8 (en) Tetrahydropyridothiophenes for use in the treatment of cancer
GB0517387D0 (en) Combinations for the treatment of cancer
ZA200709443B (en) Methods for the treatment of substance abuse and dependence
EP1904088A4 (en) COMPOSITIONS AND METHODS FOR TREATING CANCER
IL226363A0 (en) Compounds and methods for treating cancer
SI1845990T1 (sl) Zdravljenje metastaziranih tumorjev
ZA200804027B (en) Neuroendocrine tumor treatment using m TOR inhibitors
GB0516610D0 (en) Compounds for use in therapy
GB0517386D0 (en) Combinations for the treatment of cancer